AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21078419
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy regimens with anthracyclines or anthracycline/taxane combination
Trial: 21078419
Drug: EORTC QLQ-C30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EORTC QLQ-C30 (European Organization for Research and Treatment Quality of Life Questionnaire)
Trial: 21079154
Drug: BEACOPP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEACOPP chemotherapy (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)
Trial: 21079154
Drug: Consolidation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation therapy for rapid responders (females: 4 cycles of COPP/ABV without IFRT; males: 2 cycles of ABVD with IFRT)
Trial: 21079154
Drug: BEACOPP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEACOPP chemotherapy with IFRT for slow responders
Trial: 21079158
Drug: Control (age-matched,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (age-matched, no oncological treatment)
Trial: 21083543
Drug: Adalimumab retreatment
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab retreatment (80 mg at week 0 and 40 mg eow starting at week 1)
Trial: 21085552
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) consisting of 6 weekly sessions and 3 telephone booster calls.
Trial: 21086246
Drug: Lanreotide Autogel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide Autogel® 120 mg at 56-day interval
Trial: 21086246
Drug: Lanreotide Autogel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide Autogel® 120 mg at 42-day interval
Trial: 21086246
Drug: Lanreotide Autogel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide Autogel® 120 mg at 28-day interval
Trial: 21086246
Drug: Lanreotide Autogel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide Autogel® 120 mg
Trial: 21087953
Drug: Ciliary neurotrophic
RxNorm normalized name: CILIARY NEUROTROPHIC FACTOR
DrugBank: Ciliary neurotrophic factor (DB05344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciliary neurotrophic factor (CNTF) treatment delivered by an encapsulated cell technology implant in one eye
Trial: 21087958
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (1.25 mg) or ranibizumab (0.5 mg)
Trial: 21093024
Drug: AMG 317
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 317 (IL-4 receptor α antagonist)
Trial: 21093448
Drug: ANRS HIV-LIPO-5
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANRS HIV-LIPO-5 Vaccine (dendritic cell vaccine loaded with HIV-1-antigen lipopeptides)
Trial: 21093448
Drug: ANRS HIV-LIPO-5
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANRS HIV-LIPO-5 Vaccine
Trial: 21094089
Drug: Navitoclax (14/21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax (14/21 dosing schedule) at doses of 10, 20, 40, 80, 110, 160, 225, 315, or 440 mg/day
Trial: 21094089
Drug: Navitoclax (21/21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax (21/21 dosing schedule) at doses of 200, 275, 325, or 425 mg/day
Trial: 21094089
Drug: Navitoclax (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax (150 mg/day lead-in dose followed by 325 mg on continuous 21/21 schedule)
Trial: 21098436
Drug: Bioresorbable everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bioresorbable everolimus drug-eluting vascular scaffold
Trial: 21107682
Drug: Everolimus 5
RxNorm normalized name: everolimus 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 5 mg/day plus vinorelbine and trastuzumab
Trial: 21107682
Drug: Everolimus 30
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 30 mg/week plus vinorelbine and trastuzumab
Trial: 21107682
Drug: Everolimus 20
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 20 mg/week plus vinorelbine and trastuzumab
Trial: 21108818
Drug: Prepandemic (H5N1)
RxNorm normalized name: influenza, H5N1-1203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepandemic (H5N1) influenza vaccine adjuvanted with AS03A (3.75 μg haemagglutinin)
Trial: 21108818
Drug: Prepandemic (H5N1)
RxNorm normalized name: influenza, H5N1-1203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepandemic (H5N1) influenza vaccine adjuvanted with AS03A
Trial: 21109011
Drug: Tandem high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandem high-dose therapy (HDT) with autologous peripheral blood stem cell (PBSC) support; Induction with anthracyclin-containing regimen followed by tandem HDT conditioned by high-dose mitoxantrone plus cytarabine for the first HDT and total-body irradiation (TBI), carmustine, etoposide, and cyclophosphamide for the second HDT
Trial: 21109011
Drug: Tandem high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandem high-dose therapy (HDT) with autologous peripheral blood stem cell (PBSC) support
Trial: 21109229
Drug: Phototherapeutic keratectomy
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phototherapeutic keratectomy (PTK) with low-dose mitomycin C (MMC) 0.002% for 1 minute
Trial: 21111785
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (5.0mg, n=12)
Trial: 21111785
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (1.0mg, n=10)
Trial: 21115606
Drug: Daily and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily and/or weekly symptom variability
Trial: 21115606
Drug: Impact on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impact on daily activities
Trial: 21115606
Drug: Adjustment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustment of treatment
Trial: 21117946
Drug: Candesartan 32
RxNorm normalized name: candesartan 32 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 32 mg + Hydrochlorothiazide 25 mg (Phase 1)
Trial: 21117946
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg + Hydrochlorothiazide 25 mg (Phase 2)
Trial: 21117946
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg + Hydrochlorothiazide 25 mg + Amlodipine 5 mg (optional extension)
Trial: 21118739
Drug: New disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New disposable rhGH injection pen
Trial: 21123449
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) treatment for obstructive sleep apnea (OSA) for 8 weeks
Trial: 21123825
Drug: L-asparaginase-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase-based treatment
Trial: 21131369
Drug: Brivanib alaninate
RxNorm normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib alaninate at doses of 800 mg/day (continuous)
Trial: 21131369
Drug: Brivanib alaninate
RxNorm normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib alaninate at doses of 400 mg b.i.d.
Trial: 21131369
Drug: Brivanib alaninate
RxNorm normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib alaninate at doses of 800 mg/day (intermittent)
Trial: 21131369
Drug: Brivanib alaninate
RxNorm normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib alaninate at doses of 180-800 mg
Trial: 21131369
Drug: Brivanib alaninate
RxNorm normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib alaninate at doses ≤1000 mg/day
Trial: 21131369
Drug: Brivanib alaninate
RxNorm normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib alaninate at maximum tolerated dose (MTD) of 800 mg/day
Trial: 21131552
Drug: ENMD-2076 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENMD-2076 at 200 mg/m(2)
Trial: 21131552
Drug: ENMD-2076 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENMD-2076 at 160 mg/m(2) (MTD)
Trial: 21131552
Drug: ENMD-2076 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENMD-2076 (various doses: 60, 80, 120, 160, 200 mg/m(2))
Trial: 21134243
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sotrastaurin once between days 1-3 and once between days 5-8 post-transplant
Trial: 21134985
Drug: PR1 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR1 and WT1 peptides in Montanide-adjuvant with GM-CSF, administered every two weeks for a total of 6 injections
Trial: 21134985
Drug: Booster injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster injection three months after the 6th vaccine dose
Trial: 21135251
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C treatment
Trial: 21138605
Drug: Wheat bran
RxNorm normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bran (9 g)
Trial: 21138939
Drug: sFlt-1 >84
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sFlt-1 >84 ng/L
Trial: 21138939
Drug: PlGF >20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PlGF >20 ng/L
Trial: 21138939
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of troponin T and sFlt-1
Trial: 21139575
Drug: Low-dose peginterferon
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose peginterferon α2a
Trial: 21140148
Drug: Imatinib (dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (dosing modified to achieve target plasma levels)
Trial: 21142268
Drug: Exenatide ER
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide ER 0.8 mg
Trial: 21142268
Drug: Exenatide ER
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide ER 2 mg
Trial: 21143432
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release methylphenidate (OROS MPH) at a mean dose of 54 mg/day (0.90 mg/kg/day)
Trial: 21145590
Drug: Daunorubicin combined
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin combined with imatinib mesylate (600 mg/d) and cytarabine (200 mg/d for 7 days)
Trial: 21145590
Drug: Daunorubicin at
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin at 30-45 mg/m(2)/d
Trial: 21145590
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IM with a standard '3+7' regimen
Trial: 21145720
Drug: 24 μg
RxNorm normalized name: penicillin G 24 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 μg formoterol
Trial: 21145855
Drug: PEG-IFN therapy
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFN therapy (0-4 weeks)
Trial: 21145855
Drug: PEG-IFN therapy
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFN therapy (5-19 weeks)
Trial: 21145855
Drug: PEG-IFN therapy
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFN therapy (20-23 weeks)
Trial: 21145855
Drug: PEG-IFN therapy
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFN therapy (24 weeks)
Trial: 21145855
Drug: Missed doses
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Missed doses during therapy
Trial: 21148334
Drug: Surgical resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical resection followed by chemotherapy
Trial: 21148530
Drug: Adjuvanted pandemic
RxNorm normalized name: pangamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
Trial: 21148532
Drug: Monovalent 2009
RxNorm normalized name: influenza a (H1N1) virus vaccine monovalent 2009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent 2009 influenza A (H1N1) vaccine (strain A/California/7/2009H1N1)
Trial: 21148613
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg orally days 1-28, every 42 days (1 cycle)
Trial: 21149673
Drug: Lenalidomide 15
RxNorm normalized name: lenalidomide 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 15 mg/m2/dose
Trial: 21149673
Drug: Lenalidomide 40
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 40 mg/m2/dose
Trial: 21149673
Drug: Lenalidomide 55
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 55 mg/m2/dose
Trial: 21149673
Drug: Lenalidomide 70
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 70 mg/m2/dose
Trial: 21155613
Drug: rhPTH(1-84) 100
RxNorm normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhPTH(1-84) 100 μg, administered once daily as a subcutaneous injection for 12 months
Trial: 21156020
Drug: AMG 102
RxNorm normalized name: AMG 102
DrugBank: Rilotumumab (DB11972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 102 at 10 mg/kg
Trial: 21156020
Drug: AMG 102
RxNorm normalized name: AMG 102
DrugBank: Rilotumumab (DB11972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 102 at 20 mg/kg
Trial: 21156020
Drug: AMG 102
RxNorm normalized name: AMG 102
DrugBank: Rilotumumab (DB11972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 102 (both doses)
Trial: 21163497
Drug: Single patch
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single patch repair
Trial: 21163497
Drug: Double patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double patch repair
Trial: 21163497
Drug: Single atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single atrial septal defect patch with primary ventricular septal defect closure
Trial: 21163927
Drug: G-CSF (lenograstim,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (lenograstim, 263 μg)
Trial: 21167116
Drug: Trivalent seasonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent seasonal influenza vaccine (15μg of hemagglutinin of each virus strain)
Trial: 21169856
Drug: Febuxostat (40,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (40, 80, or 120 mg daily for up to 5 years)
Trial: 21170669
Drug: Saracatinib 175
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saracatinib 175 mg PO daily in combination with gemcitabine (1000 mg/m(2))
Trial: 21172791
Drug: 400/100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg lopinavir/ritonavir twice daily
Trial: 21172791
Drug: 200/150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/150 mg lopinavir/ritonavir twice daily
Trial: 21172791
Drug: 200/50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/50 mg lopinavir/ritonavir twice daily
Trial: 21173095
Drug: Subcutaneous veltuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous veltuzumab 80 mg
Trial: 21173095
Drug: Subcutaneous veltuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous veltuzumab 160 mg
Trial: 21173095
Drug: Subcutaneous veltuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous veltuzumab 320 mg
Trial: 21173095
Drug: Subcutaneous veltuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous veltuzumab (all doses combined)
Trial: 21173101
Drug: FBS0701, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FBS0701, a novel oral iron chelator, given daily for 7 days at doses up to 32 mg/kg
Trial: 21173101
Drug: FBS0701, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FBS0701, a novel oral iron chelator
Trial: 21174506
Drug: Standard-of-care with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care with atorvastatin 80 mg
Trial: 21176218
Drug: 15-20 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-20 ml/kg of 4°C cold normal saline (TH group)
Trial: 21176218
Drug: TH group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TH group with 17 ml/kg of cold saline
Trial: 21176752
Drug: Daptomycin 6
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin 6 mg/kg administered after HD during a 48 h - 48 h - 72 h dialysis week.
Trial: 21176752
Drug: Daptomycin 6
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin 6 mg/kg administered before a CAPD dwell time over a 48 h - 48 h - 48 h dialysis week.
Trial: 21177912
Drug: 4CMenB (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB (3 doses at baseline, 2 months, and 6 months)
Trial: 21177912
Drug: MenACWY-CRM (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM (1 dose 1 month after 4CMenB)
Trial: 21178394
Drug: Novel synthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel synthetic TB subunit vaccine
Trial: 21178655
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg famciclovir
Trial: 21180274
Drug: Sirolimus treatment
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus treatment after 101-200 days (n = 6)
Trial: 21188121
Drug: Resveratrol/GP (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol/GP (80 g of grape powder per day)
Trial: 21191530
Drug: Injectable risperidone
RxNorm normalized name: risperidone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable risperidone long-acting therapy (25-50mg, injected every 2 weeks)
Trial: 21191530
Drug: Oral aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral aripiprazole (5-30mg/day)
Trial: 21194015
Drug: Clock Drawing
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clock Drawing Test (CDT) administered at all time points
Trial: 21194419
Drug: Potassium control-target
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium control-target of 4.0 mmol/L
Trial: 21194419
Drug: Potassium control-target
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium control-target of 4.5 mmol/L
Trial: 21200021
Drug: Interferon α
RxNorm normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon α (IFNα) treatment
Trial: 21203574
Drug: Preparations for
RxNorm normalized name: ANTI-ACNE PREPARATIONS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparations for delivery
Trial: 21205021
Drug: Insulin stimulation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin stimulation in type 1 diabetic patients
Trial: 21206909
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg p.o. twice daily continuously
Trial: 21208151
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl orally disintegrating tablet (ODT)
Trial: 21209881
Drug: In vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo pioglitazone treatment
Trial: 21211990
Drug: Rituximab (anti-CD20)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (anti-CD20) therapy